Sort
17,828 grants matching “crispr”
Combination gene editing protocol using CRISPR technology for HIV/AIDS cure in non-human primates
$824,124Tricia Helen Burdo · Temple Univ Of The Commonwealth · R56 · FY2020 · AI
Core Center for Stem Cell and Transplantation Biology
$824,002Beverly J Torok-Storb · Fred Hutchinson Cancer Research Center · U54 · FY2019 · DK
Core Center for Stem Cell and Transplantation Biology
$824,002Beverly J Torok-Storb · Fred Hutchinson Cancer Research Center · U54 · FY2016 · DK
Core Center for Stem Cell and Transplantation Biology
$824,002Beverly J Torok-Storb · Fred Hutchinson Cancer Research Center · U54 · FY2017 · DK
Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV disease
$822,868Sulggi Angela Lee · University Of California, San Francisco · R33 · FY2025 · DA
Collaborative Pathways that Lead to Leukemia
$822,748Peter Aplan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Analysis of Innate Immune Signaling Networks
$822,670Iain Fraser · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
RNAi Screening in Hematopoietic Cells
$822,670Iain Fraser · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Centriole and ubiquitin pathway regulation of craniofacial development
$822,149Shaun Abrams · National Institute Of Dental & Craniofacial Research · ZIA · FY2025 · DE
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS
$822,075Joseph M Salvino · Alliance Discovery, Inc. · R44 · FY2017 · CA
Drosophila Transgenic RNAi Resource Project
$821,851Norbert Perrimon · Harvard Medical School · R01 · FY2017 · GM
Cytosolic DNA, Telomeres/Subtelomeres, and Epigenetics: A Longitudinal Twin Study to Assess the Role of Genetics and Environment on their Frequency and Inter-relationships
$820,469Colleen K Jackson-Cook · Virginia Commonwealth University · R01 · FY2023 · AG
The role of AU-rich element binding proteins in shaping target mRNA expression
$820,032Markus Hafner · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2015 · AR
High Throughput CRISPR/Cas9 cell line generation using the CellRaft Array
$819,896Jessica Hartman · Cell Microsystems, Inc. · R44 · FY2020 · GM
CAREER: Organic and inorganic carbon metabolism in methanotrophic bacteria.
$819,654Calvin Henard · University Of North Texas · · FY2025 · BIO
Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
$819,031Erik J Sontheimer · Univ Of Massachusetts Med Sch Worcester · UG3 · FY2020 · TR
Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology
$819,000Hongbo Chi · St. Jude Children'S Research Hospital · U01 · FY2023 · CA
Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology
$819,000Hongbo Chi · St. Jude Children'S Research Hospital · U01 · FY2025 · CA
Safety and Efficacy of Human Clinical Trials Using Kidney-on-a-Chip Microphysiological Systems
$818,669Jonathan Himmelfarb · University Of Washington · UG3 · FY2020 · TR
Systematic identification of oncogenic KRAS synthetic lethal interactions
$817,805William C Hahn · Broad Institute, Inc. · U01 · FY2015 · CA
From genetic basis to mechanisms for Heart Failure
$817,208Ling Xiao · Broad Institute, Inc. · R01 · FY2025 · HL
Evaluating the Impact of Mutations in Distant-Acting Enhancers in Structural Birth Defects
$816,999Len Alexander Pennacchio · University Of Calif-Lawrenc Berkeley Lab · R01 · FY2023 · HD
Discovering human divergent activity-regulated elements using comparative, computational, and functional approaches
$816,779Alexander A Pollen · University Of California, San Francisco · R01 · FY2025 · MH
Discovering human divergent activity-regulated elements using comparative, computational, and functional approaches
$816,779Alexander A Pollen · University Of California, San Francisco · R01 · FY2024 · MH
Aberrant proteomes in tauopathy: revealing functional consequences via multimodal proteomics
$816,661Danielle L Swaney · University Of California, San Francisco · R01 · FY2025 · AG